Posted on NaviNet Plan Central page 2-1-2017

FIVE TYPES TO BE ADDED TO MEDICAL PATHWAYS PROGRAM 4/1/17 Beginning April 1, 2017, the Highmark Medical Oncology Management Pathways Program will expand to include five additional cancer types. Providers can expect to see the new content in the Clear Value PlusSM decision support tool starting April 1, 2017. All decisions made on or after April 1, 2017, for the new will be calculated in the practice’s concordance score.

All other program components remain the same.

The following cancer types will be added to the Pathways Program starting April 1, 2017: • • Esophageal and esophageal junction cancers • Gastric cancer • Kidney cancer •

Benefits of this Pathways Program expansion include: • Access to clinical decision support for five additional cancers • Ability to provide high-quality, cost-effective care to a greater number of Highmark and non- Highmark members • Increased opportunity to improve or maintain high concordance by selecting Value Pathways for the new cancers

Effective April 1, 2017, the complete list of cancer types in the Highmark Medical Oncology Management Pathways Program will be as follows: • • Chronic myelogenous (CML) • Colon cancer • Fallopian tube cancer • : (oropharyngeal, laryngeal, hypopharyngeal) • Hodgkin’s • • • Non-Hodgkin's : (DLBCL, Follicular, CLL, SLL, Mantle Cell) • • Pancreatic adenocarcinoma • Primary peritoneal cancer • • Rectal cancer (continued)

• Small cell • Non-small cell lung cancer • Esophageal and esophagogastric junction cancers (starting 4-1-17) • Gastric cancer (starting 4-1-17) • Kidney cancer (starting 4-1-17) • Myelodysplastic syndrome (starting 4-1-17) • Bladder cancer (starting 4-1-17)